Ken Griffin Keros Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$41.68 - $58.07 $145,880 - $203,245	3,500 Added 194.44%	5,300 $307,000
Q2 2024 Aug 14, 2024	SELL	$44.58 - $66.89 $142,656 - $214,048	-3,200 Reduced 64.0%	1,800 $82,000
Q1 2024 May 15, 2024	BUY	$41.26 - $70.48 $119,654 - $204,392	2,900 Added 138.1%	5,000 $331,000
Q4 2023 Feb 14, 2024	BUY	$27.12 - $41.05 $54,240 - $82,100	2,000 Added 2000.0%	2,100 $83,000
Q3 2023 Nov 14, 2023	SELL	$31.57 - $43.02 $12,628 - $17,208	-400 Reduced 80.0%	100 $3,000
Q2 2023 Aug 14, 2023	BUY	$37.26 - $51.01 $14,904 - $20,404	400 Added 400.0%	500 $20,000
Q1 2023 May 15, 2023	BUY	$41.44 - $59.32 $4,144 - $5,932	100 New	100 $4,000

174

30.3M

76.8K

Ticker KROS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,757,000
Market Cap $1.46B
Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.